Back to results
US 5,827,735 AGranted
Pluripotent mesenchymal stem cells and methods of use thereof
AssigneeMorphoGen Pharmaceuticals, Inc.
InventorsHenry E. Young, Paul A. Lucas
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeMorphoGen Pharmaceuticals, Inc.
InventorsHenry E. Young, Paul A. Lucas
Estimating the term…
A scar inhibitory factor protein isolate from mammalian basement membranes is provided that inhibits lineage commitment and differentiation of stem cells in vitro and in vivo. The protein isolate is characterized by its ability to inhibit stem cell commitment to a fibroblastic-scar phenotype without killing the cells, thus allowing their differentiation into normal tissue phenotypes. SIF thus limits the amount of scar tissue formation at the site of delivery, while maximizing the potential for the stem cells to differentiate into other tissue phenotypes (muscle, cartilage, bone, fat, etc.). Therefore, it is useful in treating numerous disorders and injuries that currently result in scar tissue or fibrous adhesion formation. The protein isolate can be administered in various modalities in vivo, i.e., as a transdermal patch, incorporated into wound dressings, incorporated into absorbable suture material, incorporated into a bioerodible polymer matrix by itself or interspersed with differentiation factors near the site of tissue injury, sprayed onto prosthetic implants, and can be administered directly to cells cultured in vitro.
Purified pluripotent mesenchymal stem cells, which cells are substantially free of multinucleated myogenic lineage-committed cells, and which cells are predominantly stellate-shaped cells, wherein the mesenchymal stem cells form predominantly fibroblastic cells when contacted with muscle morphogenic protein in tissue culture medium containing 10% fetal calf serum and form predominantly branched multinucleated structures that spontaneously contract when contacted with muscle morphogenic protein and scar inhibitory factor in tissue culture with medium containing 10% fetal calf serum.
Purified pluripotent mesenchymal stem cells prepared by the method comprising:
A method for obtaining purified pluripotent mesenchymal stem cells comprising:
Dependencies are inferred from the claim text.